Aplitabart

Synonyms: IGM-8444
Aplitabart (IGM-8444) 是一种五聚体 IgM 死亡受体 5 (DR5) 激动性抗体,其 KD 为 85 nM、表观亲和力为 11 pM,可通过使 DR5 多聚化经外源性凋亡 (apoptosis) 通路诱导癌细胞凋亡,并可用于结直肠癌和胃癌等癌症相关研究。
产品编号: MS-J56089 纯度: 97.024% CAS No.: 2796349-94-3
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Aplitabart (IGM-8444) 是一种五聚体 IgM 死亡受体 5 (DR5) 激动性抗体,其 KD 为 85 nM、表观亲和力为 11 pM,可通过使 DR5 多聚化经外源性凋亡 (apoptosis) 通路诱导癌细胞凋亡,并可用于结直肠癌和胃癌等癌症相关研究。

生物实验数据

生物活性 Aplitabart (IGM-8444) is a pentameric IgM death receptor 5 (DR5) agonist antibody with a KD of 85 nM and an apparent affinity of 11 pM that induces cancer cell apoptosis through the extrinsic apoptosis pathway by multimerizing DR5, and can be used for cancer-related research such as colorectal cancer and gastric cancer.
IC50 & Target

DR5

 

体外研究
(In Vitro)

IGM-8444 可强效结合 Colo205 结直肠癌细胞 (EC50 = 170 ng/mL) 和 H-EMC-SS 软骨肉瘤细胞 (EC50 = 64 ng/mL)。
IGM-8444 (24 h) 可强效诱导 Colo205 结直肠癌细胞 (IC50 = 1.1 ng/mL) 和 H-EMC-SS 软骨肉瘤细胞 (IC50 = 0.32 ng/mL) 产生细胞毒性。
IGM-8444 (1 μg/mL; 0.5-6 h) 可在 Colo205 结直肠癌细胞和 H-EMC-SS 软骨肉瘤细胞中快速且强效激活 caspase-3/7、caspase-8 和 caspase-9。
IGM-8444 (1 μg/mL; 1-6 h) 处理 6 小时后,可诱导 23%的 Colo205 结直肠癌细胞和 15%的 H-EMC-SS 软骨肉瘤细胞发生早期凋亡。
IGM-8444 (72 h) 在 HCT15 结直肠癌细胞、NCI-H2228 非小细胞肺癌细胞和 MV-411 急性髓系白血病细胞中,与化疗制剂及 ABT-199 (MS-S50888) 表现出协同细胞毒性,其最大 Bliss 评分范围为 16.8 至 53.4。

Apoptosis Analysis

Cell Line: Colo205 colorectal cancer cells, H-EMC-SS chondrosarcoma cells
Concentration: 1 μg/mL
Incubation Time: 1, 3, 6 h
Result: Induced early apoptosis in 23% of Colo205 cells and 15% of H-EMC-SS cells after 6 hours of treatment.
Showed significantly more early apoptosis induction than the corresponding anti-DR5 IgG (4% and 2% early apoptotic cells for Colo205 and H-EMC-SS, respectively), which was similar to isotype controls.
体内研究
(In Vivo)

IGM-8444 (0.3-20 mg/kg;静脉注射;单次给药或隔日一次;共 11 剂) 可剂量依赖性地抑制小鼠体内 Colo205 结直肠肿瘤的生长。
IGM-8444 (5 mg/kg;静脉注射;每 2 天 1 次;共 11 剂) 可在 NCI-H2122 非小细胞肺癌异种移植物中诱导 101% 的 TGI,将中位无事件生存期延长 40 天。
IGM-8444 (0.3-10 mg/kg;静脉注射;隔日一次) 可在 GXF251 胃癌 PDX 模型中诱导强效、持续的肿瘤消退。
IGM-8444 (5 mg/kg;静脉注射;隔日一次;共 7 次给药) 与 irinotecan (MS-O02109)、5-FU (HY-90006) 或 Paclitaxel (HY-B0015) 联合使用时,可增强 Colo205 结直肠癌异种移植模型中的抗肿瘤效力。
IGM-8444 (5 mg/kg;静脉注射;每两天一次;共 11 剂) 联合 ABT-199 可在 DOHH-2 非霍奇金淋巴瘤异种移植物中诱导 102% 的 TGI 并延长小鼠生存期。

Animal Model: Crl:NU (Ncr)-Foxn1nu (female, 8-12-weeks-old, subcutaneous implantation of 2×106 Colo205 cells)
Dosage: 0.3, 1, 3 and 10 mg/kg (tumor growth inhibition); 0.3, 1, 3, 10 and 20 mg/kg (biomarker analysis)
Administration: i.v.; every other day; 11 doses (tumor growth inhibition); i.v.; single dose (biomarker analysis)
Result: Induced 23%, 29%, 75%, and 84% tumor growth inhibition (TGI) on day 22 at doses of 0.3, 1, 3, and 10 mg/kg, respectively.
Increased serum M30 up to 10-fold and M65 up to 5-fold in a dose-dependent manner 24 hours after single doses.
Animal Model: Crl:NU (Ncr)-Foxn1nu (female, 8-12-weeks-old, subcutaneous implantation of 107 NCI-H2122 cells)
Dosage: 5 mg/kg
Administration: i.v.; every other day; 11 doses (tumor growth and survival); i.v.; single dose (biomarker analysis)
Result: Induced 101% TGI on day 26, with 5/10 animals achieving a partial response (PR).
Extended median event-free survival by 40 days compared with vehicle.
Significantly elevated cleaved caspase-3 (CC3) staining in tumor tissue 24 hours after a single dose.
Animal Model: NMRI nude (female, 5-7-weeks-old, subcutaneous implantation of 3-4 mm GXF251 PDX tumor fragments)
Dosage: 0.3, 1, 3 and 10 mg/kg (dose-dependent study); 5 mg/kg (fixed dose, different tumor sizes)
Administration: i.v.; every other day; 7 doses (fixed dose); i.v.; every other day (dose-dependent study); i.v.; weekly (weekly dosing study)
Result: Induced 112% TGI on day 46 at 5 mg/kg every other day for 7 doses, with 8/10 complete responses (CR), 2/10 partial responses (PR), 7/10 event-free animals, and 6/10 tumor-free survivors (TFS) at day 99.
Elevated serum M30 10-fold and M65 6-fold 24 hours post-treatment.
Induced 30%, 55%, 101%, and 99% TGI on day 59 at doses of 0.3, 1, 3, and 10 mg/kg every other day, respectively, with 2/7 tumor-free animals in the 10 mg/kg group at day 100.
Induced 58% and 102% TGI on day 28 with weekly dosing of 1 and 10 mg/kg, respectively.
Induced 112%, 103%, and 101% TGI on day 32 when dosed into tumors with initial volumes of 100, 300, or 500 mm3, respectively.
Animal Model: Crl:NU (Ncr)-Foxn1nu (female, 8-12-weeks-old, subcutaneous implantation of 2×106 Colo205 cells)
Dosage: 5 mg/kg (single agent); 5 mg/kg + 100 mg/kg irinotecan; 5 mg/kg + 100 mg/kg 5-FU; 5 mg/kg + 25 mg/kg paclitaxel
Administration: i.v.; every other day; 7 doses (IGM-8444); i.p.; weekly; 3 weeks (Irinotecan, 5-FU); i.v.; every other day; 5 doses (Paclitaxel)
Result: Induced 70%-76% TGI as a single agent at 5 mg/kg.
Combination with Irinotecan induced 103% TGI with 2/10 PRs and extended median event-free survival by 42 days compared with vehicle.
Combination with 5-FU induced 104% TGI with 3/10 PRs and 1/10 CR/TFS, without additional toxicity compared with 5-FU alone.
Combination with paclitaxel increased CR rate from 30% (Paclitaxel alone) to 100%, with 8/10 animals tumor-free at day 100 compared with 2/10 in the Paclitaxel-only group.
Animal Model: Fox Chase SCID, CB17/Icr-Prkdcscid/IcrIcoCrl (female, 9-weeks-old, subcutaneous implantation of 107 DOHH-2 cells)
Dosage: 5 mg/kg (single agent); 5 mg/kg + 100 mg/kg ABT-199
Administration: i.v.; every other day; 11 doses (IGM-8444); p.o.; daily; 21 days (ABT-199)
Result: Induced 45% TGI as a single agent at 5 mg/kg.
Combination with ABT-199 induced 102% TGI with 3/10 PRs and 2/10 CRs.
Significantly extended median event-free survival compared with vehicle or ABT-199 alone.
Clinical Trial
性状 液体
颜色 Colorless to off-white

化学信息

CAS No. 2796349-94-3
别名 IGM-8444

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础